Palbociclib for progressive brain metastases harboring CDK pathway alterations
Dr. Priscilla Brastianos
Recent studies suggest that the CDK pathway may be a therapeutic target for brain metastases (BMs). A basket trial evaluating the intracranial activity of the CDK inhibitor palbociclib in patients with progressive BMs and CDK alterations met its primary endpoint, and provides evidence for performing molecular testing of archival BM tissue to inform the choice of CNS-penetrant targeted therapy.
